Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

Journal of Clinical Pharmacology

Volumn 48, Issue 5, 2008, Pages 592-598

  Mistry, Goutam C ^a   Maes, Andrea L ^a   Lasseter, Kenneth C ^b   Davies, Michael J ^a   Gottesdiener, Keith M ^a   Wagner, John A ^a   Herman, Gary A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Clinical Pharmacology Associates Miami   (United States)

Author keywords

Blood pressure; DPP 4; Incretin; Sitagliptin

Indexed keywords

ANTIHYPERTENSIVE AGENT; PLACEBO; SITAGLIPTIN;

ARTICLE; BLOOD PRESSURE MONITORING; BORDERLINE HYPERTENSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CROSS-OVER STUDIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 41849099939     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008316885     Document Type: Article

References (15)

1. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006 ; 60: 1454-1470.
2. Drucker DJ Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003 ; 26: 2929-2940.
3. Drucker DJ The role of gut hormones in glucose homeostasis. J Clin Invest. 2007 ; 117: 24-32.
4. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol. 1994 ; 266: E459 - E466.
5. Yamamoto H., Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002 ; 110: 43-52.
6. Toft-Nielsen MB, Madsbad S., Holst JJ Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999 ; 22: 1137-1143.
7. Drucker DJ, Nauck MA GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet. 2006 ; 368: 1696-1705.
8. Arauz-Pacheco C., Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003 ; 26 (Suppl 1). S80 - S82.
9. Bergman AJ, Stevens C., Zhou YY, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006 ; 28: 55-72.
10. JANUVIA (sitagliptin) [package insert]. Whitehouse Station, NJ: Merck & Co Inc ; 2007.
11. Nathwani A., LeBeaut A., Byiers S., Gimpelewicz C., Chang I. Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes. Diabetes. 2006 ; 55 (Suppl 1). A113.
12. Herman GA, Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharm Therap. 2005 ; 78: 675-688.
13. Anderson EA, Balon TW, Hoffman RP, Sinkey CA, Mark AL Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension. 1992 ; 19: 621-627.
14. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991 ; 87: 2246-2252.
15. Wang JG, Staessen JA, Franklin SS, Fagard R., Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005 ; 45: 907-913.